Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.

Arthritis Res Ther · 2022 · PMC8728910 · PMID 34986869

Europe PMC DOI

hedged sentence

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

did not reach statistical significancep = 0.098so close (0.05 < p ≤ 0.1)

We also observed a trend for acazicolcept-mediated decreases in CD3+ T cells by 37% in the skin of HOCL/acazicolcept-treated mice compared to HOCL/Fc control-treated mice, although this difference did not reach statistical significance ( p = 0.098) (Fig. 3 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.